Related Experiment Video

Updated: Apr 25, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.7K

Effects of tirofiban on platelet activation and endothelial function in patients with ST-elevation myocardial

Kuan Wang1, Guoxing Zuo, Liuying Zheng

  • 1The fifth central hospital of Tianjin, No. 41 Zhejiang road, BinHai new area, Tianjin, China.

Cell Biochemistry and Biophysics
|August 16, 2014
PubMed

Insights

Tirofiban, a platelet aggregation inhibitor, reduced platelet activation and endothelial dysfunction in ST-segment-elevated myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI). This treatment improved myocardial reperfusion and left ventricular function.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biomedical Engineering

Background:

  • ST-segment-elevated myocardial infarction (STEMI) is a critical condition requiring prompt intervention.
  • Percutaneous coronary intervention (PCI) is a standard treatment for STEMI.
  • Platelet activation and endothelial dysfunction are key contributors to STEMI pathophysiology and outcomes.

Purpose of the Study:

  • To investigate the effect of intracoronary tirofiban on platelet activation and endothelial dysfunction in STEMI patients undergoing PCI.
  • To evaluate the impact of tirofiban on myocardial reperfusion and left ventricular function post-PCI.

Main Methods:

  • A pilot study randomized 119 STEMI patients into a tirofiban group (intracoronary and intravenous administration) and a control group.
  • Platelet activation markers (CD62P, PAC-1) and endothelial dysfunction markers (endothelial microparticles, VCAM-1, ICAM-1) were measured.
  • Left ventricular ejection fraction and ST-segment resolution (STR) were assessed post-PCI.

Main Results:

  • Tirofiban significantly reduced markers of platelet activation and endothelial dysfunction 48 hours after PCI.
  • The tirofiban group showed a higher incidence of complete STR and improved left ventricular ejection fractions at 10 days post-PCI.
  • No significant difference in clinical outcomes was observed between groups at two weeks.

Conclusions:

  • Periprocedural intracoronary tirofiban attenuates platelet activation and endothelial dysfunction in STEMI patients undergoing PCI.
  • Tirofiban administration may contribute to improved myocardial reperfusion and preservation of left ventricular systolic function.
  • Further research is warranted to confirm long-term clinical benefits.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K
Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.0K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.9K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.1K
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
519